Healthtech startup Mesh Bio in Singapore raises $1.8 M in seed funding

Singapore-based healthtech startup Mesh Bio has raised $1.8 million (SGD2.4 million) in Seed funding, led by deep tech investors and Enterprise Singapore’s investment arm Seeds Capital, along with Citrine Capital and Tael Partners.

The funds will be used to accelerate the rollout of Mesh Bio’s solution, DARA® – a predictive analytics and clinical workflow automation solution for healthcare providers – in Southeast Asia and Hong Kong. The funding will also support clinical partnerships and collaborations.


Mesh Bio raises US$1.8M seed to help doctors predict diseases before they occur

Mesh Bio, a Singaporean health-tech startup, has raised US$1.8 million in a seed funding round, led by deep-tech investor and SEEDS capital.

Wealth management firm Citrine Capital as well as Singaporean VC firm Tael Partners also joined the round. 

Mesh Bio intends to use the capital to accelerate the rollout of its solution, DARA, for healthcare providers in Southeast Asia and Hong Kong. The funds will also support the startup’s clinical partnerships and collaborations.

Mesh Bio intends to expand its solution further across Southeast Asia and Hong Kong.



Entrepreneur First’s Latest European Cohort Revealed, With Plenty Of Biotech Startups On Show

Amidst the global lockdowns and coronavirus precautions, Entrepreneur Firstopted to reveal their latest European cohort virtually, through pre-recorded pitch videos.


Investor and media demand clearly was high for the 13th European cohort’s reveal, as the dedicated website for the online demo day initially crashed due to too much traffic at its 1 p.m. launch time. But after some wrangling behind-the-scenes, the teams from London, Berlin and Paris were on show for the first time.

EF was founded in 2011 by Alice Bentinck and Matt Clifford, and is well-known for their non-traditional approach to the entrepreneurial path. Instead of selecting companies with existing business ideas for their cohorts, individuals are chosen based on their technical and business talent, and EF works with them to create high-growth startups from scratch.

The focus has shifted over the last two years, with synthetic biology startups emerging amongst the AI and machine learning companies. As Clifford puts it: “We’re increasingly seeing that the world’s most talented and ambitious people are motivated to solve huge problems in the [life science] space, and we are hitting an inflection point where the barriers to entry to building a breakout biotech company are dramatically reducing.”

Some of the life science focuses include animal-free dairy, gene therapies for treating donor livers, genetic information capturing and digital twins of cells to accelerate drug discovery.

With the spotlight shifting somewhat towards life sciences at EF still being a relatively new approach, it will be intriguing to see how their talent-first method fares in this rapidly accelerating market; building successful biotech companies is, after all, no mean feat.